lonidamine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, Y; Qin, Y; Wang, D; Wang, X; Wang, Z; Zhang, L; Zhang, T; Zhu, Y | 1 |
1 other study(ies) available for lonidamine and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Glutathione Programmed Mitochondria Targeted Delivery of Lonidamine for Effective Against Triple Negative Breast Cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Glutathione; Humans; Mice; Mitochondria; Nanoparticles; Triple Negative Breast Neoplasms | 2023 |